GlobalData’s detailed strategic reports on the MFN executive order and on the GENEROUS model examined how some of the known ...

After signing a drug pricing deal with the White House, J&J will now offer some of its branded medicines at discounted rates ...

CDMOs are re-evaluating a reliance on China and increasingly turning to nearshoring and friendshoring for supply chain ...

Sino Biological launched its Center for Bioprocessing (C4B) at the heart of the Texas Medical Center hub in Houston, Texas, ...

Santhera Pharmaceuticals has entered into an exclusive licensing agreement with Nxera Pharma for Agamree to treat DMD in ...

With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

Alveus Therapeutics has debuted with $160m in Series A financing, as the biotech looks to join the crowded obesity sector ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer ...

Octapharma has received approval from the US FDA for a new 2-g formulation of Fibryga for use in patients with AFD.

Zai Lab has received approval from China’s NMPA for the sNDA for Augtyro to treat adult patients with solid tumours ...